Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 13.2% during trading on Thursday . The stock traded as high as $0.37 and last traded at $0.36. Approximately 85,764,556 shares changed hands during mid-day trading, an increase of 13% from the average daily volume of 76,209,492 shares. The stock had previously closed at $0.32.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a report on Friday, January 17th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Up 3.4 %

The firm has a market cap of $61.67 million, a PE ratio of -0.01 and a beta of 2.02. The firm’s 50-day moving average price is $0.27 and its two-hundred day moving average price is $0.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.